ReviewCancer gene therapy2006
Transductional targeting of adenovirus vectors for gene therapy.
Review in Cancer gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 131 citations in OpenAlex.
- Transduction of Brain Neurons in Juvenile Chum Salmon (International journal of molecular sciences · 2022Article
- Adenovirus Fibers as Ultra-Stable Vehicles for Intracellular Nanoparticle and Protein Delivery.Biomolecules · 2022Article
- The Inflammatory and Fibrotic Patterns of Hepatic Stellate Cells Following Coagulation Factors (VII or X)-Shielded Adenovirus Infection.Current microbiology · 2021Article
- Amphiphilic Polyphenylene Dendron Conjugates for Surface Remodeling of Adenovirus 5.Angewandte Chemie (International ed. in English) · 2020Article
- Oncolytic Virotherapy for Breast Cancer Treatment.Current gene therapy · 2018Review
- Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.Oncotarget · 2017Article
- Targeting Melanoma with Cancer-Killing Viruses.The open virology journal · 2017Article
- Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.Oncotarget · 2016Article
- Article
- Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.Molecular therapy oncolytics · 2015Article
- Adenoviral targeting using genetically incorporated camelid single variable domains.Laboratory investigation; a journal of technical methods and pathology · 2014Article
- The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting.Laboratory investigation; a journal of technical methods and pathology · 2014Article
- Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer.Viruses · 2014Review
- Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: a mathematical model.PloS one · 2014Article
- Article
- Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.PloS one · 2014Article
- Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.Virology · 2013Article
- General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.Current gene therapy · 2013Review
- Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model.Laboratory investigation; a journal of technical methods and pathology · 2013Article
- An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer gene therapy approaches will derive considerable benefit from adenovirus (Ad) vectors capable of self-directed localization to neoplastic disease or immunomodulatory targets in vivo. The ablation of native Ad tropism coupled with active targeting modalities has demonstrated that innate gene delivery efficiency may be retained while circumventing Ad dependence on its primary cellular receptor, the coxsackie and Ad receptor. Herein, we describe advances in Ad targeting that are predicated on a fundamental understanding of vector/cell interplay. Further, we propose strategies by which existing paradigms, such as nanotechnology, may be combined with Ad vectors to form advanced delivery vehicles with multiple functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.